Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of AL8326 in Advanced Small Cell Lung Cancer
NCT06247605Phase 3Recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Oct 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AL8326 in small cell lung cancer (SCLC), sponsored by Advenchen Laboratories. Started Oct 2023; status: recruiting.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06247605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247605.